Blood test results and fibrinolysis markers at diagnosis and follow-up for 79 patients with hematological cancer
| . | At diagnosis . | At follow-up . | P value . | Reference range . |
|---|---|---|---|---|
| Standard blood tests | ||||
| B–hemoglobin, mmol/L, mean (95% CI) | 7.9 (7.6-8.3) | 7.4 (6.9-7.8) | .27 | 7.3-10.5 |
| B–platelet count, 109/L, mean (95% CI) | 318 (275-361) | 231 (195-268) | .06 | 145-400 |
| B–leucocyte count, 109/L, median (95% CI) | 8.9 (7.4-10.6) | 4.7 (3.9-5.7) | .003 | 3.5-10 |
| P–creatinine, μmol/L, median (95% CI) | 71 (67-75) | 75 (69-82) | .52 | 45-105 |
| P–C-reactive protein, mg/L, median (IQR) | 4 (8.1) | 4 (2.5) | .09 | <8 |
| Coagulation tests | ||||
| P–INR, median (IQR) | 1 (0.1) | 1 (0.1) | .27 | <1.2 |
| P–aPTT, s, median (IQR) | 25 (5.8) | 25 (4.5) | .94 | 20-29 |
| P–D-dimer, mg/L, median (IQR) | 0.58 (0.9) | 0.44 (0.6) | .02 | <0.5 |
| P–fibrinogen, μmol/L, mean (95% CI) | 10.5 (9.8-11.3) | 10.66 (9.79-11.53) | .63 | 5.5-12.0 |
| Clot lysis assay | ||||
| Peak absorbance, AU, mean (95% CI) | 0.66 (0.61-0.71) | 0.68 (0.62-0.74) | .40 | 0.18-0.74 |
| 50% clot lysis time, s, median (95% CI) | 698 (620-786) | 817 (716-933) | .03 | 309-1565 |
| AUC, median (95% CI) | 691 (599-797) | 788 (670-927) | .007 | 219-1051 |
| Fibrinolysis enzymes and proteins | ||||
| P–α2-AP activity, % mean (95% CI) | 115 (111-120) | 125 (115-134) | .02 | 75-135 |
| P–PAI-1, ng/mL, median (95% CI) | 7.8 (6-10.1) | 9.3 (6.9-12.4) | .20 | 7.0-43.0 |
| P–PAP, ng/mL, median (95% CI) | 355 (296-426) | 235 (190-290) | .003 | 0-514 |
| P–PLG activity, % mean (95% CI) | 109 (104-113) | 112 (104-120) | .69 | 70-130 |
| P–tPA, ng/mL, median (95% CI) | 2.7 (2.5-2.9) | 3 (2.6-3.6) | .13 | 2.0-8.0 |
| P–uPA, ng/mL, median (95% CI) | 0.7 (0.6-0.7) | 0.7 (0.6-0.7) | .29 | 1.2-2.4 |
| . | At diagnosis . | At follow-up . | P value . | Reference range . |
|---|---|---|---|---|
| Standard blood tests | ||||
| B–hemoglobin, mmol/L, mean (95% CI) | 7.9 (7.6-8.3) | 7.4 (6.9-7.8) | .27 | 7.3-10.5 |
| B–platelet count, 109/L, mean (95% CI) | 318 (275-361) | 231 (195-268) | .06 | 145-400 |
| B–leucocyte count, 109/L, median (95% CI) | 8.9 (7.4-10.6) | 4.7 (3.9-5.7) | .003 | 3.5-10 |
| P–creatinine, μmol/L, median (95% CI) | 71 (67-75) | 75 (69-82) | .52 | 45-105 |
| P–C-reactive protein, mg/L, median (IQR) | 4 (8.1) | 4 (2.5) | .09 | <8 |
| Coagulation tests | ||||
| P–INR, median (IQR) | 1 (0.1) | 1 (0.1) | .27 | <1.2 |
| P–aPTT, s, median (IQR) | 25 (5.8) | 25 (4.5) | .94 | 20-29 |
| P–D-dimer, mg/L, median (IQR) | 0.58 (0.9) | 0.44 (0.6) | .02 | <0.5 |
| P–fibrinogen, μmol/L, mean (95% CI) | 10.5 (9.8-11.3) | 10.66 (9.79-11.53) | .63 | 5.5-12.0 |
| Clot lysis assay | ||||
| Peak absorbance, AU, mean (95% CI) | 0.66 (0.61-0.71) | 0.68 (0.62-0.74) | .40 | 0.18-0.74 |
| 50% clot lysis time, s, median (95% CI) | 698 (620-786) | 817 (716-933) | .03 | 309-1565 |
| AUC, median (95% CI) | 691 (599-797) | 788 (670-927) | .007 | 219-1051 |
| Fibrinolysis enzymes and proteins | ||||
| P–α2-AP activity, % mean (95% CI) | 115 (111-120) | 125 (115-134) | .02 | 75-135 |
| P–PAI-1, ng/mL, median (95% CI) | 7.8 (6-10.1) | 9.3 (6.9-12.4) | .20 | 7.0-43.0 |
| P–PAP, ng/mL, median (95% CI) | 355 (296-426) | 235 (190-290) | .003 | 0-514 |
| P–PLG activity, % mean (95% CI) | 109 (104-113) | 112 (104-120) | .69 | 70-130 |
| P–tPA, ng/mL, median (95% CI) | 2.7 (2.5-2.9) | 3 (2.6-3.6) | .13 | 2.0-8.0 |
| P–uPA, ng/mL, median (95% CI) | 0.7 (0.6-0.7) | 0.7 (0.6-0.7) | .29 | 1.2-2.4 |
Reference ranges for hemoglobin and platelet counts for men and women have been combined.
AUC, area under the curve; B, blood; CI, confidence interval; IQR, interquartile range; P, plasma; PLG, plasminogen.